Wierda WG , Leow CC, Ruppert AS, Bian Y, Woyach JA . Reply to: How to Interpret the Results in a Noninferiority Randomized Trial in Chronic Lymphocytic Leukemia. J Clin Oncol:JCO2600304, 2026. e-Pub 2026. PMID: 42008785.
— 2026cited by 0position: selected
Bazinet A, Ferrajoli A, Jain N, Burger JA, Yilmaz M, Swaminathan M, Kantarjian HM, Keating M, Thompson PA, Wierda WG . NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy. Blood Adv, 2026. e-Pub 2026. PMID: 41879712.
— 2026cited by 0position: selected
Soumerai JD, Wierda WG . Developing MRD as an early endpoint for accelerated approval in CLL. Semin Hematol, 2026. e-Pub 2026. PMID: 41986213.
— 2026cited by 0position: selected
Brown JR, Nguyen B, Desikan SP, Won H, Tantawy SI, McNeely SC, Marella N, Randeria HS, Hanson LM, Parker A, Botelho SC, Woyach JA, Patel K, Tam CS, Eyre TA, Cheah CY, Shah NN, Ghia P, Jurczak W, Balbas M, Nair B, Abada P, Wang C, Wang D, Roeker LE, Gandhi V, Wierda WG . Genomic determinants of respo
— 2026cited by 0position: selected
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE study.
Wierda WG . Highlights in chronic lymphocytic leukemia from the 66th ASH Annual Meeting and Exposition: commentary. Clin Adv Hematol Oncol 23 Suppl 1(1):3-13, 2025. e-Pub 2025. PMID: 39907565.
— 2025cited by 0position: selected
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial
CLL-269 Pirtobrutinib in Relapsed/Refractory CLL/SLL: Results From BTK-Naïve Cohort in the Phase 1/2 BRUIN Study
Pirtobrutinib in Relapsed/Refractory CLL/SLL: Results From BTK-Naïve Cohort in the Phase 1/2 BRUIN Study
Wierda WG . The approval of lisocabtagene maraleucel in chronic lymphocytic leukemia. Clin Adv Hematol Oncol 22(6):291-293, 2024. e-Pub 2024. PMID: 39110651.
— 2024cited by 0position: selected
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study
Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome
A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies
Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia
Relapse after First-Line Fixed Duration Ibrutinib + Venetoclax: High Response Rates to Ibrutinib Retreatment and Absence of BTK Mutations in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) with up to 5 Years of Follow-up in the Phase 2 Captivate Study
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
Pirtobrutinib in Post-cBTKi CLL/SLL: ~30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study
Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study
Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter's Transformation: An International Multicenter Retrospective Study
Thompson PA, Keating MJ, Ferrajoli A, Jain N, Peterson CB, Garg N, Wang SA, Jorgensen JL, Kadia TM, Bose P, Pemmaraju N, Short NJ, Wierda WG . Venetoclax consolidation in high-risk CLL treated with ibrutinib for >/=1 year achieves a high rate of undetectable MRD. Leukemia 37(7):1444-1453, 2023. e-Pu
— 2023cited by 0position: selected
Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W . A phase 2 study of nivolum
— 2023cited by 0position: selected
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study
Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study
Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL)